We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Exenatide: AC 2993, AC002993, AC2993A, Exendin 4, LY2148568.
- Authors
Adis International Limited
- Abstract
Exenatide [AC002993, AC2993A, AC 2993, LY2148568, exendin 4], a glucagon-like peptide-1 (GLP-1) agonist, is a synthetic exendin 4 compound under development with Amylin Pharmaceuticals for the treatment of type 2 diabetes. Both exendin 4 and its analogue, exendin 3, are 39-amino acid peptides isolated from Heloderma horridum lizard venom that have different amino acids at positions 2 and 3, respectively. Exendins are able to stimulate insulin secretion in response to rising blood glucose levels, and modulate gastric emptying to slow the entry of ingested sugars into the bloodstream. Amylin Pharmaceuticals acquired exclusive patent rights for the two exendin compounds (exendin 3 and exendin 4) from the originator, Dr John Eng (Bronx, NY, US). On 20 September 2002, Amylin and Eli Lilly signed a collaborative agreement for the development and commercialisation of exenatide for type 2 diabetes. Under the terms of the agreement, Eli Lilly has paid Amylin a licensing fee of $80 million and bought Amylin's stock worth $30 million at $18.69 a share. After the initial payment, Eli Lilly will pay Amylin up to $85 million upon reaching certain milestones and also make an additional payment of up to $130 million upon global commercialisation of exenatide. Both companies will share the US development and commercialisation costs, while Eli Lilly will pick up up to 80% of development costs and all commercialisation costs outside the US. Amylin and Eli Lilly will equally share profit from sales in the US, while Eli Lilly will get 80% of the profit outside the US and Amylin will get the rest. This agreement has also enabled Amylin to train its sales force to co-promote Lilly's human growth hormone Humatrope[sup ®]. Alkermes will receive research and development funding and milestone payments, and also a combination of royalty payments and manufacturing fees based on product sales. Alkermes undertakes the responsibility for the development of several initial formulations of t...
- Subjects
AMYLIN Pharmaceuticals Inc.; TREATMENT of diabetes; AMINO acids; COMMERCIAL products; COMMERCIALIZATION; ELI Lilly &; Co.
- Publication
Drugs in R&D, 2004, Vol 5, Issue 1, p35
- ISSN
1174-5886
- Publication type
Article